Hinova Pharmaceuticals Inc.
Hinova Pharmaceuticals is a Chengdu-based company listed on Shanghai's STAR Market (SSE: 688302). Its deuterated enzalutamide HC-1119 was approved in China in May 2025 for prostate cancer, and a Phase 3 study in high-risk biochemical recurrence has been cleared.
| Headquarters | Chengdu, China |
|---|---|
| Listing | SSE:688302 |
| Lead asset / stage | HC-1119 (deuterated enzalutamide) Approved — China |
| Latest event | Hinova announced China clinical-trial approval for a Phase 3 HC-1119 study in high-risk biochemical recurrent prostate cancer. |